Genmab — Maj 2017
-
Jeg kan se Novod skrev "We still believe in a likely guidance upgrade later in the year and now see focus turning back onto strong pipeline news over the next 12 months, starting with JnJ's CMD on 17 May and ASCO by late May. We maintain our Buy rating and raise our DCF-based target price to DKK 1,577 (1,570).
-
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement Copenhagen, Denmark; May 16, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 43,252 shares as a...
GlobeNewswire News Room (globenewswire.com)
-
-
Iøvrigt påvirkes fair value også af den risikofaktor hvormed godt de kan forudsige indtjening samt historikken. Jo bedre data jo højere pris resulterer det i og omvendt. I tilfældet Genmab er man ikke i det allermest forudsigelige hjørne - kilde Nordea naturligvis. - Så vi fortsætter bare med at kigge opad

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind